Status:
RECRUITING
Intermittent Fasting and Mediterranean Diet in Patient With Multiple Sclerosis
Lead Sponsor:
Nigde Omer Halisdemir University
Collaborating Sponsors:
Acibadem University
Conditions:
Multiple Sclerosis
Intermittent Fasting
Eligibility:
FEMALE
18-65 years
Phase:
NA
Brief Summary
When the literature was reviewed, there is no study in which the effects of intermittent fasting and Mediterranean diet on quality of life, sleep, circadian rhythm and appetite hormones leptin and ghr...
Detailed Description
Multiple Sclerosis (MS) is the most common chronic inflammatory disease affecting young adults between the ages of 20-40 years, which causes irreversible neurological damage and symptoms and is influe...
Eligibility Criteria
Inclusion
- To apply to the neurology outpatient clinic, to be a female between the ages of 18-65 who has been diagnosed with MS by a physician
- Not being in the attack period
- Not being in menopause Not being diagnosed with any autoimmune system disease other than -MS that may adversely affect the study,
- Not following the Mediterranean diet and intermittent fasting programmes in the last three months,
- Not being diagnosed with an eating behaviour disorder,
- Not having any communication problems,
- Signing the informed consent form,
- Brain MRI within the last three months,
- Not to be pregnant and lactating
- No physical disability No history of cancer
- Body Mass Index between 18,5 kg/m2- 29,9 kg/m2,
- Not losing 5% and/or more body weight in the last month
Exclusion
- Having a diagnosis of autoimmune system disease that may adversely affect working outside of -MS,
- To be in the attack period-Being under 18 years of age and over 65 years of age
- Being in menopause-Mediterranean diet and intermittent fasting feeding programmes within the last three months,
- Diet therapy that has an effect on the autoimmune system within the last three months,
- Being diagnosed with eating behaviour disorder,
- Having any communication problems,- Not signing the informed consent form,
- Failure to adapt to the work during the working period, to be in a situation/behaviour that may adversely affect the work,
- To have applied any nutritional intervention during the last three months prior to the study,
- Taking supplements such as selenium, zinc, iron, vitamin D and/or B12, which may affect the course of the study,
- To have received cancer treatment and / or to be receiving cancer treatment,
- Other neurological diseases (e.g. Parkinson's, epilepsy, Alzheimer's),
- Diagnosed with a disease lasting more than 4 months in the last 12 months and other specialised dietary / compositionally different dietary patterns (e.g. high protein, ketogenic, low energy content \< 1000 kcal/day),
- Body Mass Index \<18.5 kg/m2 or \>30 kg/m2
- Losing 5% and/or more body weight in the last month,
- Having a physical disability
Key Trial Info
Start Date :
May 2 2024
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 2 2026
Estimated Enrollment :
34 Patients enrolled
Trial Details
Trial ID
NCT06546033
Start Date
May 2 2024
End Date
December 2 2026
Last Update
August 9 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Nigde Omer Halisdemir University
Niğde, Bor, Turkey (Türkiye), 51200